Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVR-C5252
- Development stage
- Phase 1
- Lead developer
- ImmVira
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Small Molecules, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intratumoral
01
Overview
MVR-C5252 is a genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1) designed for the treatment of malignant glioma and other high-grade brain tumors. Developed by ImmVira using its OvPENS platform, this recombinant viral therapy is further attenuated from the earlier candidate MVR-T3011 to enhance tumor selectivity and safety. The virus has been modified to express two exogenous genes—interleukin-12 (IL-12), an immunostimulatory cytokine, and an anti-PD-1 monoclonal antibody—to stimulate immune responses within the tumor microenvironment and promote direct oncolytic activity against malignant gliocytes. The drug is currently in Phase 1 clinical trials for recurrent high-grade glioma/glioblastoma in the United States and has received orphan drug designation for glioma[3][4][6][8].
- Other names
- MVR C5252C5252疱疹病毒
02
Targets
IL-12R (Interleukin-12 receptor)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MVR-C5252.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVR-C5252.